Alcobra Limited Ord (NASDAQ:ADHD) Shorts Decreased by 0.85% After Short Covering


The stock of Alcobra Limited Ord (NASDAQ:ADHD) registered a decrease of 0.85% in short interest. ADHD’s total short interest was 2.47 million shares in September as published by FINRA. Its down 0.85% from 2.49M shares, reported previously. With 145,800 shares average volume, it will take short sellers 17 days to cover their ADHD’s short positions. The short interest to Alcobra Limited Ord’s float is 19.84%. About 81,343 shares traded hands. Alcobra Ltd (NASDAQ:ADHD) has declined 3.85% since February 8, 2016 and is downtrending. It has underperformed by 20.34% the S&P500.

Alcobra Ltd is an Israel-based Biopharmaceutical company. The company has a market cap of $124.13 million. It focuses on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder , a common and morbid neuropsychiatric condition in children and adults. It currently has negative earnings. Adult ADHD is associated with increased health risks and healthcare costs, higher divorce rates, lower levels of socioeconomic attainment, lower academic achievement, unemployment and work place deficits, increased risks for motor vehicle accidents, greater likelihood of additional psychiatric disorders, increased criminal activity and incarceration, and higher rates of substance use and abuse.

Out of 5 analysts covering Alcobra Pharma (NASDAQ:ADHD), 4 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 80% are positive. $16 is the highest target while $8 is the lowest. The $13.33 average target is 191.05% above today’s ($4.58) stock price. Alcobra Pharma has been the topic of 6 analyst reports since January 25, 2016 according to StockzIntelligence Inc. Barclays Capital initiated the stock on August 1 with “Equal-Weight” rating. Cantor Fitzgerald initiated the shares of ADHD in a report on June 7 with “Buy” rating.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Reply